Heat Biologics, Inc.
HTBXAMEXHealthcare
$2.38
+$0.01(+0.42%)
Market Cap$61074370
P/E Ratio—
52W High$2.48
52W Low$2.33
Heat Biologics, Inc. (HTBX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · HTBX · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2021-12 | 2020-12 | 2019-12 | 2018-12 | 2017-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.11M | $2.95M | $3.05M | $5.79M | $1.52M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $2.11M | $2.95M | $3.05M | $5.79M | $1.52M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $18.82M | $12.94M | $13.01M | $16.23M | $8.27M |
| G&A Expenses | $16.83M | $15.00M | $9.43M | $7.03M | $0.00M |
| Total Operating Expenses | $37.53M | $27.94M | $22.44M | $23.26M | $14.64M |
| Operating Income | ($35.42M) | ($26.12M) | ($20.75M) | ($17.96M) | ($13.34M) |
| Operating Margin %(computed) | — | -886.18% | -680.39% | -309.99% | -877.85% |
| Interest Income | $0.82M | $0.57M | $0.43M | $0.27M | $0.02M |
| Interest Expense | $0.13M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($35.55M) | ($26.38M) | ($20.34M) | ($17.58M) | ($13.22M) |
| Income Tax Expense | ($0.15M) | ($0.26M) | $0.05M | ($0.99M) | ($0.81M) |
| Net Income | ($35.40M) | ($26.05M) | ($20.02M) | ($15.73M) | ($11.84M) |
| Net Margin %(computed) | — | -883.65% | -656.51% | -271.56% | -779.09% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.41 | $-1.63 | $-4.21 | $-6.30 | $-21.56 |
| Wtd Avg Shares | 25.14M | 15.98M | 4.75M | 2.50M | 0.55M |
| EBITDA | ($35.55M) | ($25.72M) | ($19.74M) | ($16.48M) | ($12.52M) |
| EBITDA Margin %(computed) | — | -872.35% | -647.40% | -284.47% | -823.53% |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Heat Biologics, Inc. data
About Heat Biologics, Inc. (HTBX) Income Statement
Heat Biologics, Inc. (HTBX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2021, HTBX reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.04B) — a net profit margin of -1675.54%.
Frequently asked questions
HTBX · 4 questionsHeat Biologics, Inc. (HTBX) reported revenue of $0.00B for 2021, down 28.3% year-over-year.
HTBX revenueHTBX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09